oncology stocks

  • Enhertu Double Approval, Regeneron Miss: What It Means for Smaller Biotechs

    Enhertu Double Approval, Regeneron Miss: What It Means for Smaller Biotechs

    Two FDA decisions landed on the same Monday and pulled the sector in opposite directions. AstraZeneca and Daiichi Sankyo’s Enhertu picked up two new approvals in early breast cancer. Regeneron dropped 12% after its melanoma trial missed statistical significance against Keytruda. One validated a platform that smaller biotechs are actively building on. The other confirmed…

    read more